Ex Vivo Virotherapy With Myxoma Virus Does Not Impair Hematopoietic Stem and Progenitor Cells

BACKGROUND: Relapsing disease is a major challenge after hematopoietic cell transplant for hematological malignancies. Myxoma virus (MYXV) is an oncolytic virus that can target and eliminate contaminating cancer cells from auto-transplant grafts. The aims of this study were to examine the impact of...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Cytotherapy
Main Authors: Villa, Nancy Y., Bais, Swarna, Meacham, Amy M., Wise, Elizabeth, Rahman, Masmudur M., Moreb, Jan S, Rosenau, Emma H., Wingard, John R., McFadden, Grant, Cogle, Christopher R.
Format: Artigo
Jezik:Inglês
Izdano: 2016
Teme:
Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC4748395/
https://ncbi.nlm.nih.gov/pubmed/26857235
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jcyt.2015.12.007
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki